Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide with Carboplatin/Etoposide in SCLC
NCT00061919Phase 3Completed
- Sponsor
- University College London
- Start
- Apr 2003
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Active arm (thalidomide) with Placebo arm (2 arms). Primary endpoint: Overall Survival at 2 years. Started Apr 2003; status: completed.
02
Drugs
thalidomide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00061919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061919.